Full-Time
Associate Therapy Consultant
Mid Atlantic South
Updated on 8/11/2026
NeuroPace
201-500 employees
Implantable brain-responsive neuromodulation for epilepsy
Compensation Overview
$90k/yr
Richmond, VA, USA
Hybrid
Approximately 80% travel to customer clinics, hospitals, and offsite meetings is required.
Bachelor's
 Sales & Account Management (1) |
|---|
Get referred to NeuroPace
See people who can refer or advise you
- Minimum 1-3 years of sales experience within the medical device industry.
- A bachelor's degree in a relevant field such as Life Sciences or Business is required.
- Experience with Class III implantable devices is preferred.
- Demonstrated verbal, written communication, and presentation skills are required.
- Prior exposure to neurology, neuromodulation, or surgical specialties is preferred.
- Strong understanding of clinical workflows and patient care dynamics is required.
- Demonstrated success in a fast-paced, field-based healthcare environment is required.
- Approximately 80% travel to customer clinics, hospitals, and offsite meetings is required.
- A valid driver's license is required.
- Assist in setting an aggressive sales strategy to develop new accounts and grow existing account business in the assigned area.
- Develop physician champions for product adoption in new accounts while increasing the user base per generator.
- Serve as a key field resource for competitive positioning in target accounts.
- Use consultative or solution-need selling skills in customer interactions.
- Establish relationships with physicians and allied health professionals, specifically epileptologists, neurologists, and neurosurgeons in the territory.
- Manage customer education and training and drive participation in company-sponsored educational and training programs.
- Educate customers on the merits and proper clinical usage of the RNS System through presentations and demonstrations using slides, clinical sheets, an iPad, manuals, and other formats.
- Manage patients through all phases of the clinical process and educate them on NeuroPace product features and benefits.
- Work with Field Clinical Engineers to implement Patient Education Programs at key accounts.
- Cover surgical cases and support Therapy Consultants with operating-room logistics and patient workflow.
- Support in-clinic patient programming and educate clinicians on the NeuroPace RNS System.
- Work with Field Clinical Engineers to support patient education events, including EFA meetings and support groups.
- Use Caspio for patient pipeline management and Salesforce CRM.
- Work with the Primary Therapy Consultant and Regional Management on territory performance, sales, customer satisfaction, business-plan execution, and reporting.
- Drive patient identification by working with referring physicians and epilepsy coordinators.
- Build and maintain relationships with local neurologists and epileptologists to drive community referrals.
- Track and report referral activity, clinic utilization, and case support in Salesforce.com.
- Maintain clinical credibility while developing foundational sales skills and business-planning exposure.
- Experience with Class III implantable devices.
- Prior exposure to neurology, neuromodulation, or surgical specialties.
NeuroPace develops the RNS System, a brain-responsive neuromodulation device for treating refractory epilepsy. The implanted system monitors brain activity and delivers targeted electrical stimulation when abnormal patterns are detected to reduce seizures. Clinicians receive data and analysis to guide therapy, and the company sells devices with ongoing support. The goal is to broaden adoption, expand to other neurological disorders, and grow revenue while improving seizure control and quality of life for patients.
Company Size
201-500
Company Stage
IPO
Headquarters
Mountain View, California
Founded
1999
Get referred to NeuroPace
See people who can refer or advise you
Simplify's Take
What believers are saying
- CMS boosted 2026 Medicare pay for RNS implants and replacements on January 1.
- Q1 2026 revenue hit $22.1 million, while RNS sales offset DIXI runoff.
- NeuroPace raised 2026 revenue guidance to $98-$100 million and targets IGE expansion.
What critics are saying
- NeuroPace exits DIXI by June 30, 2026, removing diversification and revenue smoothing.
- Q2 2026 results on August 11 face a tough comp after Q1's flat revenue.
- FDA or CMS delays on PDMS and IGE expansion trap NeuroPace inside a single epilepsy niche.
What makes NeuroPace unique
- NeuroPace's RNS captures months of intracranial EEG, a dataset rivals lack.
- On May 29, 2026, FDA cleared ECoG Assistant, adding AI workflow differentiation.
- Stanford-rooted closed-loop epilepsy therapy combines implant, software, and remote programming.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Health Savings Account/Flexible Spending Account
Paid Vacation
Paid Holidays
Remote Work Options
529 plan
Employee Stock Purchase Plan
Company Equity
Training Programs
Wellness Program
Commuter Benefits
Growth & Insights and Company News
6 month growth
↑ 1%1 year growth
↑ 0%2 year growth
↑ 0%NeuroPace (NPCE) expected to release earnings on Tuesday. August 4, 2026 Key points. * NeuroPace is expected to report Q2 2026 results after the market closes on August 11. Analysts forecast a loss of $0.19 per share and revenue of approximately $22.6 million. * In the previous quarter, NeuroPace reported a smaller-than-expected loss of $0.13 per share and revenue of $22.0 million, exceeding consensus estimates. * Shares recently traded at $13.78, below their 50-day and 200-day moving averages. Analysts maintain a consensus "Moderate Buy" rating with an average price target of $19.29, while institutional investors own 78.83% of the stock. * Five stocks to consider instead of NeuroPace. NeuroPace (NASDAQ:NPCE - Get Free Report) is projected to post its Q2 2026 results after the market closes on Tuesday, August 11th. Analysts expect the company to post earnings of ($0.19) per share and revenue of $22.6130 million for the quarter. Parties may visit the the company's upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 8:00 AM ET. NeuroPace (NASDAQ:NPCE - Get Free Report) last posted its earnings results on Tuesday, May 12th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.06. NeuroPace had a negative net margin of 21.67% and a negative return on equity of 108.20%. The firm had revenue of $22.00 million during the quarter, compared to the consensus estimate of $21.65 million. NeuroPace stock performance. Shares of NASDAQ:NPCE traded up $0.28 during midday trading on Tuesday, reaching $13.78. 60,627 shares of the company traded hands, compared to its average volume of 202,962. The firm's fifty day moving average price is $15.84 and its two-hundred day moving average price is $15.51. The firm has a market capitalization of $469.86 million, a price-to-earnings ratio of -21.19 and a beta of 1.92. The company has a quick ratio of 4.35, a current ratio of 5.38 and a debt-to-equity ratio of 4.08. NeuroPace has a 12 month low of $7.56 and a 12 month high of $19.60. Institutional trading of NeuroPace. A number of institutional investors have recently modified their holdings of NPCE. Legal & General Group Plc increased its holdings in shares of NeuroPace by 86.0% in the 2nd quarter. Legal & General Group Plc now owns 2,679 shares of the company's stock worth $30,000 after acquiring an additional 1,239 shares during the period. Quarry LP boosted its holdings in NeuroPace by 94.9% during the third quarter. Quarry LP now owns 3,845 shares of the company's stock worth $40,000 after buying an additional 1,872 shares in the last quarter. Man Group plc increased its holdings in shares of NeuroPace by 9.7% in the fourth quarter. Man Group plc now owns 21,626 shares of the company's stock valued at $334,000 after buying an additional 1,920 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of NeuroPace by 23.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,836 shares of the company's stock worth $230,000 after acquiring an additional 2,778 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new position in shares of NeuroPace in the 2nd quarter worth $35,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors. Wall Street analysts forecast growth. Several equities research analysts have recently weighed in on NPCE shares. HC Wainwright reiterated a "buy" rating and set a $20.00 price target on shares of NeuroPace in a research report on Wednesday, July 29th. Guggenheim reiterated a "neutral" rating on shares of NeuroPace in a research note on Wednesday, July 29th. Mizuho initiated coverage on shares of NeuroPace in a report on Thursday, July 23rd. They issued an "outperform" rating and a $22.00 price target for the company. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of NeuroPace in a report on Wednesday, June 24th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $19.29. Discover more Stocks & Bonds NeuroPace company profile. NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company's mission centers on delivering closed-loop, "smart" therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE. The company's flagship product, the RNS(R) System, is an implantable device designed for adults with medically refractory focal epilepsy. Further reading. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider NeuroPace, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeuroPace wasn't on the list. While NeuroPace currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The space race is growing fast, and you don't have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
NeuroPace has received FDA approval for ECoG Assistant, the first AI-driven tool designed to assist epilepsy care using long-term intracranial EEG data. The feature was announced on 29 May. Built on 124,450 epileptologist-labelled records, the tool enables physicians to review trends and timing patterns across months through integrated reports and charts, improving efficiency in data review and treatment decisions. Chief Medical Officer Martha Morrell called it an "important advancement" for faster clinical insights. The company unveiled the technology at the ASSFN Annual Meeting on 30 May. NeuroPace has submitted its next-generation patient data platform for FDA review, targeting approval in the second quarter of 2026. The company develops implantable devices for treating epilepsy and neurological conditions.
NeuroPace, Inc. (NPCE) Reveals FDA Approval of ECoG Assistant(TM). Published on june 27, 2026 at 11:31 am by fatima gulzar in news. On May 29, NeuroPace, Inc. (NASDAQ:NPCE) said it received U.S. Food and Drug Administration approval for ECoG Assistant, the first "AI-driven clinician-enabled feature." It is designed to help epilepsy care using long-term intracranial EEG data. Built on 124,450 epileptologist-labeled records, the company reported that the tool has "ECoGs of Interest." It allows physicians to review trends and timing patterns across months through integrated reports and charts, improving efficiency in data review and treatment decisions. Chief Medical Officer Martha Morrell said the feature "represents an important advancement," with faster access to insights for more informed care. CEO Joel Becker said the approval shows how the firm's data advantage is moving toward "practical tools for clinicians." NeuroPace, Inc. (NASDAQ:NPCE) debuted the technology at the ASSFN Annual Meeting on May 30. It has submitted its next-generation patient data platform for FDA review, targeting approval in the second quarter of 2026. NeuroPace, Inc. (NASDAQ:NPCE) creates, produces, and markets implantable devices to treat epilepsy and neurological illnesses. It offers implantable components such as the RNS neurostimulator and depth and cortical strip leads. While we acknowledge the risk and potential of NPCE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than NPCE and that has 10,000% upside potential, check out our report about the cheapest AI stock.
NeuroPace to highlight expanding role of responsive neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting. -ASSFN program to feature thalamic neuromodulation, NAUTILUS data in idiopathic generalized epilepsy, and emerging applications for broader epilepsy populations- -NeuroPace to engage neurosurgeon community through clinical education, product feedback sessions, and hands-on booth demonstrations- MOUNTAIN VIEW, Calif.-(BUSINESS WIRE)-NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will participate in the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting, taking place May 29 - June 2, 2026 in Cleveland, Ohio. At the meeting, NeuroPace will highlight the expanding role of responsive neuromodulation in epilepsy care, including long-term clinical outcomes with the RNS(R) System, NAUTILUS results in idiopathic generalized epilepsy (IGE), and the continued evolution of data-driven tools that support treatment planning, patient management and practice development. "Neurosurgeons are essential to expanding access to device-based therapy for drug-resistant epilepsy," said Joel Becker, President and Chief Executive Officer of NeuroPace. "ASSFN gives us an opportunity to engage directly with the physicians who are advancing the field, share practical experience with responsive neuromodulation, and support the education and training needed to bring personalized, data-informed therapy to more patients. As we continue to build evidence across focal epilepsy, IGE and other clinical applications, neurosurgeon partnership is critical." Key NeuroPace-related activities at ASSFN include: Thalamic Neuromodulation and Emerging Epilepsy Applications Presenter: Martha Morrell, MD, FAES, Chief Medical Officer, NeuroPace Date: Monday, June 1, 2026 Time: 7:00 a.m. ET * NeuroPace will host a breakfast scientific symposium focused on thalamic neuromodulation, including NAUTILUS data in IGE and emerging clinical discussions around broader epilepsy populations, including Lennox-Gastaut syndrome. * The session will highlight the growing body of evidence supporting responsive neuromodulation and the potential role of the RNS System across a broader range of patients with drug-resistant epilepsy. Epilepsy Surgery Education and Practice Development Date: Saturday, May 30, 2026 Time: 8:30 a.m. - 12:00 p.m. ET * ASSFN Special Course 1: NeuroPace is supporting ASSFN educational programming focused on epilepsy surgery fundamentals and clinical challenges, reflecting the Company's commitment to advancing physician education and expanding access to appropriate epilepsy care. Tech Suite: Product Feedback Location: Booth #107, 5th Floor Exhibit Hall * ECoG Assistant(TM), NeuroPace's recently FDA-approved AI-enabled tool, designed to further support clinical decision making through deeper data insights and more efficient ECoG review, will be available for preview in the NeuroPace Tech Suite. * NeuroPace will conduct product feedback sessions with physicians throughout the meeting to gather input on current and future RNS System capabilities, including next-generation product development priorities. * Members of NeuroPace's executive team will also hold one-on-one meetings with clinicians and key opinion leaders to discuss clinical practice trends, unmet needs and the future of responsive neuromodulation. Visit NeuroPace at ASSFN Throughout the meeting, NeuroPace team members will be available at the Company's booth (#107) to meet with neurosurgeons and care teams, discuss RNS System therapy, and provide demonstrations of tools and resources designed to support patient identification, education and long-term management. NeuroPace's Patient Educator and Nurse Navigator teams will also be available to discuss how the Company supports patients and clinical programs throughout the treatment journey. About NeuroPace, Inc. Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders. Forward Looking Statements This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. NeuroPace may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements regarding: NeuroPace's expectations, forecasts and beliefs with respect to potential indication expansion for its RNS System, including through its NAUTILUS clinical trial PMA-S submission to the FDA, and its software, technology and other product development efforts and increasing access to and adoption of RNS therapy as the standard of care in drug-resistant epilepsy. These statements are neither promises nor guarantees but involve known and unknown risks, uncertainties, and other important factors that may cause NeuroPace's actual results or events to be materially different from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties related to market acceptance and adoption of NeuroPace's RNS System; risks related to regulatory compliance and expectations for regulatory submissions and approvals to expand the market for NeuroPace's RNS System, including risks related to the NAUTILUS PMA-S submission. These and other risks and uncertainties include those described more fully in the section titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in NeuroPace's public filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 3, 2026, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 12, 2026, as well as any other reports that it may file with the SEC in the future. Forward-looking statements contained in this announcement are based on information available to NeuroPace as of the date hereof. NeuroPace undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing NeuroPace's views as of any date subsequent to the date of this press release and should not be relied upon as a prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of NeuroPace. Contacts. Investor Contact: Scott Schaper Head of Investor Relations [email protected] [email protected] More News From NeuroPace, Inc. MOUNTAIN VIEW, Calif.-( BUSINESS WIRE )-NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced FDA approval of ECoG Assistant, its first AI-driven clinician-enabled feature. This milestone represents an important step in NeuroPace's broader AI platform strategy, leveraging the world's only long-term intracranial EEG dataset to transform how epilepsy is monitored and managed. ECoG Assistant: Treatment Insights Si... MOUNTAIN VIEW, Calif.-( BUSINESS WIRE )-NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. First Quarter 2026 Highlights Total revenue of $22.1 million in the quarter. Excluding DIXI Medical, total revenue of $22.0 million representing 20.1% year over year growth RNS System revenue of $21.7 million in the quarter, r... MOUNTAIN VIEW, Calif.-( BUSINESS WIRE )-NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the first quarter of 2026 after market close on Tuesday, May 12, 2026. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). Investors interested in listening to the conference call may do so by accessing...
NeuroPace is shifting focus to its core RNS franchise whilst exiting DIXI distribution, positioning software alongside hardware as its next growth driver. The company has launched ECoG Assistant, its first commercial AI workflow tool designed to help clinicians review intracranial electroencephalography more efficiently and identify seizures with reduced manual effort. The firm is migrating its clinician platform to the cloud to enable faster software updates and support growth without increasing support burden proportionally. These workflow improvements aim to help comprehensive epilepsy centres manage larger patient panels more efficiently. NeuroPace's differentiator remains its continuous brain activity data paired with remote review, allowing clinicians to refine therapy programming over time. Clinical momentum and a potential expansion into idiopathic generalised epilepsy remain key factors, though timing and coverage dynamics continue to influence revenue trajectory.